Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney

Medical School, University of Tampere, Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
Kidney International (Impact Factor: 8.52). 01/2009; 74(11):1371-3. DOI: 10.1038/ki.2008.424
Source: PubMed

ABSTRACT Vitamin D receptor (VDR) activation has a beneficial influence on the progression of experimental renal insufficiency, and reduced renal tissue renin expression may play a role in this process. Freundlich and co-workers now report that VDR activation also suppresses the expression of angiotensinogen, angiotensin II type 1 receptor, and renin receptor in the kidneys of 5/6 nephrectomized rats, effects associated with reduced blood pressure and urinary protein excretion and with alleviated renal tissue damage.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Intestinal calcium (Ca(2+)) absorption occurs via paracellular and transcellular pathways. While the transcellular route has been extensively studied, mechanisms mediating paracellular absorption are largely unexplored. Unlike passive diffusion, secondarily active paracellular Ca(2+) uptake occurs against an electrochemical gradient with water flux providing the driving force. Water movement is dictated by concentration differences that are largely determined by Na(+) fluxes. Consequently, we hypothesized that Na(+) absorption mediates Ca(2+) flux. NHE3 is central to intestinal Na(+) absorption. NHE3 knockout mice (NHE3(-/-)) display impaired intestinal Na+, water and Ca(2+) absorption. However, the mechanism mediating this latter abnormality is not clear. To investigate this, we used Ussing chambers to measure net Ca(2+) absorption across different segments of wild-type mouse intestine. The caecum was the only segment with net Ca(2+) absorption. Quantitative RT-PCR measurements revealed caecal expression of all genes implicated in intestinal Ca(2+) absorption, including NHE3. We therefore employed this segment for further studies. Inhibition of NHE3 with 100 µM 5-(N-Ethyl-N-isopropyl) amiloride decreased luminal to serosal and increased serosal to luminal Ca(2+) flux. NHE3(-/-) mice had a >60% decrease in luminal to serosal Ca(2+) flux. Ussing chambers experiments under altered voltage clamps (-25, 0, +25 mV) showed decreased transcellular and secondarily active paracellular Ca(2+) absorption in NHE3(-/-) mice relative to wild-type animals. Consistent with this, caecal Trpv6 expression was diminished in NHE3(-/-) mice. Together these results implicate NHE3 in intestinal Ca(2+) absorption and support the theory that this is, at least partially, due to the role of NHE3 in Na(+) and water absorption.
    AJP Gastrointestinal and Liver Physiology 06/2013; 305(4). DOI:10.1152/ajpgi.00490.2012 · 3.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To review the inter-relationships between calcium, phosphorus, parathyroid hormone (PTH), parent and activated vitamin D metabolites (vitamin D, 25(OH)-vitamin D, 1,25(OH)2 -vitamin D, 24,25(OH)2 -vitamin D), and fibroblast growth factor-23 (FGF-23) during chronic kidney disease (CKD) in dogs and cats. Human and veterinary literature. Beneficial effects of calcitriol treatment during CKD have traditionally been attributed to regulation of PTH but new perspectives emphasize direct renoprotective actions independent of PTH and calcium. It is now apparent that calcitriol exerts an important effect on renal tubular reclamation of filtered 25(OH)-vitamin D, which may be important in maintaining adequate circulating 25(OH)-vitamin D. This in turn may be vital for important pleiotropic actions in peripheral tissues through autocrine/paracrine mechanisms that impact the health of those local tissues. Limited information is available reporting the benefit of calcitriol treatment in dogs and cats with CKD. A survival benefit has been shown for dogs with CKD treated with calcitriol compared to placebo. The concentrations of circulating 25(OH)-vitamin D have recently been shown to be low in people and dogs with CKD and are related to survival in people with CKD. Combination therapy for people with CKD using both parental and activated vitamin D compounds is common in human nephrology and there is a developing emphasis using combination treatment with activated vitamin D and renin-angiotensin-aldosterone-system (RAAS) inhibitors.
    03/2013; 23(2):134-62. DOI:10.1111/vec.12036
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evidence linking vitamin D to cardiovascular (CV) health has accumulated in recent years: numerous epidemiologic studies report deficiency as a significant CV risk factor, and rodent models suggest that active vitamin D can modulate critical remodeling processes, including cardiac hypertrophy and extracellular matrix remodeling. The presence of vitamin D signaling machinery within the human heart implies a direct role for this hormone in cardiac physiology and may explain associations between vitamin D status and CV outcomes. Heart failure (HF) represents a growing social and economic burden worldwide. Myocardial remodeling is central to HF development, and in the context of emerging evidence supporting mechanistic involvement of vitamin D, this review provides critical appraisal of scientific literature related to the role of vitamin D in CV disease, including data from epidemiologic and supplementation studies, as well as novel findings from animal models and in vitro work. Although associative data linking vitamin D and CV outcomes and evidence supporting a role for vitamin D in relevant pathogenic processes are both substantial, there are limited mechanistic data to indicate vitamin D supplementation as a viable therapeutic adjunct for the prevention of HF development following myocardial injury.
    Journal of cardiac failure 10/2013; 19(10):692-711. DOI:10.1016/j.cardfail.2013.09.002 · 3.07 Impact Factor

Full-text (2 Sources)

Available from
Nov 10, 2014